Despite these limitations, our findings provide novel insights into the transcriptional regulation of immune evasion in EGFR/TP53 co-mutated NSCLC and highlight the STAT1/ETS1 axis as a promising therapeutic target, laying important groundwork for future mechanistic and translational studies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.